The objectives of the Developmental Projects Program are to ensure a continual renewal of high-quality scientific endeavors in the DF/HCC Prostate Cancer SPORE and to fund efforts that will complement or enhance the overall quality of the DF/HCC Prostate Cancer SPORE. In general, the Developmental Projects Program has funded established investigators. Based on our review, we will be mindful of including more junior investigators. This Program will rely on the infrastructure created by the Administrative, Evaluation, and Planning Core (Core A) to: 1. Solicit applications and/or identify novel prostate cancer research projects 2. Evaluate these projects for funding 3. Fund innovative developmental projects 4. Re-evaluate projects for possible transition into full project status 5. Evaluate the success of the program

Public Health Relevance

The Developmental Research Program of the DF/HCC Prostate Cancel- Program is intended to attract established investigators to the field of prostate cancer in order to develop new ideas of investigation which may change the field or be developed into full projects in the SPORE.

National Institute of Health (NIH)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Chen, Eddy J; Sowalsky, Adam G; Gao, Shuai et al. (2015) Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res 21:1273-80
Labbé, D P; Zadra, G; Ebot, E M et al. (2015) Role of diet in prostate cancer: the epigenetic link. Oncogene 34:4683-91
Sowalsky, Adam G; Xia, Zheng; Wang, Liguo et al. (2015) Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer. Mol Cancer Res 13:98-106
Penney, Kathryn L; Sinnott, Jennifer A; Tyekucheva, Svitlana et al. (2015) Association of prostate cancer risk variants with gene expression in normal and tumor tissue. Cancer Epidemiol Biomarkers Prev 24:255-60
Yu, Ziyang; Chen, Sen; Sowalsky, Adam G et al. (2014) Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res 20:1590-600
Crowe, Francesca L; Appleby, Paul N; Travis, Ruth C et al. (2014) Circulating fatty acids and prostate cancer risk: individual participant meta-analysis of prospective studies. J Natl Cancer Inst 106:
Cato, Laura; Neeb, Antje; Brown, Myles et al. (2014) Control of steroid receptor dynamics and function by genomic actions of the cochaperones p23 and Bag-1L. Nucl Recept Signal 12:e005
Sun, T; Wang, X; He, H H et al. (2014) MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. Oncogene 33:2790-800
Priolo, Carmen; Pyne, Saumyadipta; Rose, Joshua et al. (2014) AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer. Cancer Res 74:7198-204
Kissick, Haydn T; Sanda, Martin G; Dunn, Laura K et al. (2014) Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response. PLoS One 9:e93231

Showing the most recent 10 out of 149 publications